Immunic (IMUX) Net Cash Flow (2013 - 2026)

Immunic has disclosed Net Cash Flow across 14 years of filings, most recently posting $171.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $171.3 million, up 885.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.8 million (up 308.72% YoY), and the FY2025 annual result was -$20.4 million, down 94.39% from the prior year.
• Net Cash Flow came in at $171.3 million for Q1 2026 at Immunic, up from -$19.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $171.3 million in Q1 2026 to a low of -$22.9 million in Q4 2024.
• The 5-year median for Net Cash Flow is -$14.1 million (2023), against an average of $5.9 million.
• Across the five-year window, Net Cash Flow slumped 257.84% in 2023 and surged 885.13% in 2026, its largest moves.
• Immunic's Net Cash Flow stood at $31.3 million in 2022, then plunged by 143.4% to -$13.6 million in 2023, then plunged by 68.45% to -$22.9 million in 2024, then rose by 15.97% to -$19.2 million in 2025, then jumped by 990.86% to $171.3 million in 2026.
• The last three Net Cash Flow figures came in at $171.3 million (Q1 2026), -$19.2 million (Q4 2025), and -$20.2 million (Q3 2025), per Business Quant data.